CELULARITY INC-A (CELU)

US1511902041 - Common Stock

2.33  +0.1 (+4.72%)

After market: 2.26 -0.07 (-3%)

Fundamental Rating

1

Overall CELU gets a fundamental rating of 1 out of 10. We evaluated CELU against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of CELU have multiple concerns. CELU does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CELU has reported negative net income.
In the past year CELU has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CELU reported negative net income in multiple years.
In the past 5 years CELU always reported negative operating cash flow.

1.2 Ratios

CELU has a Return On Assets of -83.27%. This is in the lower half of the industry: CELU underperforms 70.27% of its industry peers.
Looking at the Return On Equity, with a value of -405.70%, CELU is doing worse than 77.52% of the companies in the same industry.
Industry RankSector Rank
ROA -83.27%
ROE -405.7%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of CELU (60.24%) is better than 79.47% of its industry peers.
The Profit Margin and Operating Margin are not available for CELU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for CELU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CELU has an Altman-Z score of -9.92. This is a bad value and indicates that CELU is not financially healthy and even has some risk of bankruptcy.
CELU's Altman-Z score of -9.92 is on the low side compared to the rest of the industry. CELU is outperformed by 73.81% of its industry peers.
A Debt/Equity ratio of 1.47 is on the high side and indicates that CELU has dependencies on debt financing.
With a Debt to Equity ratio value of 1.47, CELU is not doing good in the industry: 80.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.47
Debt/FCF N/A
Altman-Z -9.92
ROIC/WACCN/A
WACC11.48%

2.3 Liquidity

CELU has a Current Ratio of 0.26. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.26, CELU is doing worse than 96.11% of the companies in the same industry.
CELU has a Quick Ratio of 0.26. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.22, CELU is not doing good in the industry: 96.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.22

More info and screens

3

3. Growth

3.1 Past

CELU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.70%.
The Revenue has grown by 182.02% in the past year. This is a very strong growth!
EPS 1Y (TTM)-10.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
Revenue 1Y (TTM)182.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%312.22%

3.2 Future

Based on estimates for the next years, CELU will show a decrease in Earnings Per Share. The EPS will decrease by -9.54% on average per year.
CELU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.52% yearly.
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CELU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CELU's earnings are expected to decrease with -9.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CELU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (12/20/2024, 8:01:17 PM)

After market: 2.26 -0.07 (-3%)

2.33

+0.1 (+4.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2024-08-28/amc
Earnings (Next)12-31 2024-12-31/amc
Inst Owners14.77%
Inst Owner Change-95.95%
Ins Owners15.54%
Ins Owner Change0%
Market Cap52.38M
Analysts82.86
Price TargetN/A
Short Float %6.5%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 5.01
EV/EBITDA N/A
EPS(TTM)-5.77
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS1.9
BVpS1.24
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.27%
ROE -405.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.24%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.99%
Cap/Sales 2.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.22
Altman-Z -9.92
F-Score4
WACC11.48%
ROIC/WACCN/A
Cap/Depr(3y)56.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)25.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)182.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%312.22%
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%
EBIT growth 1Y-196.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.59%
OCF growth 3YN/A
OCF growth 5YN/A